ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects. ACR325 is... ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.
- Mechanism
- Curator reviewed
ACR325 is a dopaminergic stabiliser. The compound significantly increases the level of dopamine and noradrenalin in the forebrain and concurrently inhibits the over-activity of dopamine in other regions of the brain without unwanted inhibitory effect on motor activity.
- Primary indication
- Investigated for use/treatment in affective disorders, bipolar disorders, and psychosis.Curator reviewed
- Code names
- ACR325
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Ordopidine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account